474941-22-5

Basic information

• Product Name: 3-(2-dimethylamino-ethoxy)-4-trifluoromethylaniline
• Synonyms: 3-(2-dimethylamino-ethoxy)-4-trifluoromethylaniline
• CAS NO: 474941-22-5
• Molecular Weight: 248.248
• Mol File: 474941-22-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(2-dimethylamino-ethoxy)-4-trifluoromethylaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-dimethylamino-ethoxy)-4-trifluoromethylaniline(474941-22-5)
• EPA Substance Registry System: 3-(2-dimethylamino-ethoxy)-4-trifluoromethylaniline(474941-22-5)

Safety Data

• Hazardous Substances Data: 474941-22-5(Hazardous Substances Data)

Upstream product

• 69411-67-2 2-fluoro-4-nitro-1-(trifluoromethyl)benzene 
• 5458-84-4 2-iodo-5-nitroanisole 
• 453560-74-2 2-methoxy-4-nitro-1-(trifluoromethyl)benzene 
• 474953-31-6 1-nitro-3-(2-dimethylamino-ethoxy)-4-trifluoromethylbenzene 
• 612498-85-8 3-nitro-6-trifluoromethylphenol 

Downstream Products

• 769961-28-6 [2-(5-isothiocyanato-2-trifluoromethyl-phenoxy)-ethyl]-dimethyl-amine 
• 474953-21-4 C₁₉H₂₂BrF₃N₂O₅S 

Relevant articles and documents

Deconstruction of sulfonamide inhibitors of the urotensin receptor (UT) and design and synthesis of benzylamine and benzylsulfone antagonists

Potent small molecule antagonists of the urotensin receptor are described. These inhibitors were derived via systematically deconstructing a literature inhibitor to understand the basic pharmacophore and key molecular features required to inhibit the prot

FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS

The invention relates to compounds of the formulae (I) to (III) wherein the substituents are as defined in the specification. These compounds have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Accordingly, the compounds of the formulae (I) to (III) would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmological conditions, proliferative diseases, inflammatory diseases, and other pathological conditions as described in the specification.